ArticleClinicoEconomics and outcomes research : CEOR2025
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].
Niodita Gupta-Werner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.